AZD1390
Product Specifications
UNSPSC Description
AZD1390 is a potent, highly selective, orally bioavailable, brain-penetrant ATM inhibitor with an IC50 of 0.78 nM in cell[1].
Target Antigen
ATM/ATR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage;PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/AZD1390.html
Purity
99.28
Solubility
DMSO : 5 mg/mL (ultrasonic;warming;heat to 60°C)
Smiles
O=C(N1C(C)C)N(C)C2=C1C3=CC(C4=CC=C(OCCCN5CCCCC5)N=C4)=C(F)C=C3N=C2
Molecular Weight
477.57
References & Citations
[1]Durant ST, et al. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Sci Adv. 2018 Jun 20;4(6):eaat1719.|[2]J. Kahn, et al. Next-Generation ATM Kinase Inhibitors Under Development Radiosensitize Glioblastoma With Conformal Radiation in a Mouse Orthotopic Model. IJROBP. 2017. 99, 600-601.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-109566/AZD1390-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-109566/AZD1390-SDS-MedChemExpress.pdf
Clinical Information
Phase 1
CAS Number
2089288-03-7
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6338464-01 0.1 mL
PTCRA, CT (PTCRA, Pre T-cell antigen receptor alpha, pT-alpha-TCR) (MaxLight 490)
Ask
View Details